Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys

Fuhua Xu, Timothy M. Hazzard, Amanda Evans, Stephen Charnock-Jones, Stephen Smith, Richard Stouffer

    Research output: Contribution to journalArticle

    30 Citations (Scopus)

    Abstract

    To determine if anti-angiogenic agents disrupt primate ovarian function, vehicle or a general angiostatic compound (TNP-470), specific antagonists of vascular endothelial growth factor (soluble VEGF receptor-1, sVEGFR-1; anti-VEGF monoclonal antibody, VEGF Ab) and/or an angiopoietin antagonist (Ang-2) were administered to rhesus monkeys: (1) locally via injection into the preovulatory follicle at midcycle or the developing corpus luteum at the midluteal phase; or (2) systemically via subcutaneous injection in the early follicular phase or at midcycle during the natural menstrual cycle. Compared to controls, intrafollicular injection of TNP-470 or sVEGFR-1 decreased circulating progesterone (P) levels in the subsequent luteal phase. Treatment with sVEGFR-1, but not TNP-470, also decreased the incidence of ovulation. Intrafollicular injection of Ang-2 also prevented ovulation, as well as any functional luteal phase. In the absence of elevated P, serum estradiol levels rose to peak levels 11-12 days post-Ang-2 treatment, at which time another large antral follicle was observed on the contralateral (noninjected) ovary. Intraluteal and systemic injection of VEGF antagonists alone or with Ang-2 had minimal effects. Thus, anti-angiogenic factors can act locally in the primate follicle to disrupt the gametogenic (oocyte release) and endocrine (steroid) functions of the ovary. However, further studies are needed to optimize delivery of angiogenic agents before they can be meaningfully evaluated as possible contraceptive agents.

    Original languageEnglish (US)
    Pages (from-to)239-248
    Number of pages10
    JournalContraception
    Volume71
    Issue number4
    DOIs
    StatePublished - Apr 2005

    Fingerprint

    Menstrual Cycle
    Vascular Endothelial Growth Factor A
    Haplorhini
    Injections
    Luteal Phase
    Ovulation
    Primates
    Ovary
    Angiopoietins
    Vascular Endothelial Growth Factor Receptor
    Follicular Phase
    Angiogenesis Inducing Agents
    Corpus Luteum
    Subcutaneous Injections
    Contraceptive Agents
    Macaca mulatta
    Oocytes
    Progesterone
    Estradiol
    Steroids

    Keywords

    • Angiopoietin-2
    • Corpus luteum function
    • Ovarian disruption
    • Ovulation
    • Rhesus monkeys
    • Vascular endothelial growth factor
    • VEGF

    ASJC Scopus subject areas

    • Medicine(all)
    • Obstetrics and Gynecology

    Cite this

    Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys. / Xu, Fuhua; Hazzard, Timothy M.; Evans, Amanda; Charnock-Jones, Stephen; Smith, Stephen; Stouffer, Richard.

    In: Contraception, Vol. 71, No. 4, 04.2005, p. 239-248.

    Research output: Contribution to journalArticle

    Xu, Fuhua ; Hazzard, Timothy M. ; Evans, Amanda ; Charnock-Jones, Stephen ; Smith, Stephen ; Stouffer, Richard. / Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys. In: Contraception. 2005 ; Vol. 71, No. 4. pp. 239-248.
    @article{ac15a23409774c30ae3323506d00bdc2,
    title = "Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys",
    abstract = "To determine if anti-angiogenic agents disrupt primate ovarian function, vehicle or a general angiostatic compound (TNP-470), specific antagonists of vascular endothelial growth factor (soluble VEGF receptor-1, sVEGFR-1; anti-VEGF monoclonal antibody, VEGF Ab) and/or an angiopoietin antagonist (Ang-2) were administered to rhesus monkeys: (1) locally via injection into the preovulatory follicle at midcycle or the developing corpus luteum at the midluteal phase; or (2) systemically via subcutaneous injection in the early follicular phase or at midcycle during the natural menstrual cycle. Compared to controls, intrafollicular injection of TNP-470 or sVEGFR-1 decreased circulating progesterone (P) levels in the subsequent luteal phase. Treatment with sVEGFR-1, but not TNP-470, also decreased the incidence of ovulation. Intrafollicular injection of Ang-2 also prevented ovulation, as well as any functional luteal phase. In the absence of elevated P, serum estradiol levels rose to peak levels 11-12 days post-Ang-2 treatment, at which time another large antral follicle was observed on the contralateral (noninjected) ovary. Intraluteal and systemic injection of VEGF antagonists alone or with Ang-2 had minimal effects. Thus, anti-angiogenic factors can act locally in the primate follicle to disrupt the gametogenic (oocyte release) and endocrine (steroid) functions of the ovary. However, further studies are needed to optimize delivery of angiogenic agents before they can be meaningfully evaluated as possible contraceptive agents.",
    keywords = "Angiopoietin-2, Corpus luteum function, Ovarian disruption, Ovulation, Rhesus monkeys, Vascular endothelial growth factor, VEGF",
    author = "Fuhua Xu and Hazzard, {Timothy M.} and Amanda Evans and Stephen Charnock-Jones and Stephen Smith and Richard Stouffer",
    year = "2005",
    month = "4",
    doi = "10.1016/j.contraception.2004.12.017",
    language = "English (US)",
    volume = "71",
    pages = "239--248",
    journal = "Contraception",
    issn = "0010-7824",
    publisher = "Elsevier USA",
    number = "4",

    }

    TY - JOUR

    T1 - Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys

    AU - Xu, Fuhua

    AU - Hazzard, Timothy M.

    AU - Evans, Amanda

    AU - Charnock-Jones, Stephen

    AU - Smith, Stephen

    AU - Stouffer, Richard

    PY - 2005/4

    Y1 - 2005/4

    N2 - To determine if anti-angiogenic agents disrupt primate ovarian function, vehicle or a general angiostatic compound (TNP-470), specific antagonists of vascular endothelial growth factor (soluble VEGF receptor-1, sVEGFR-1; anti-VEGF monoclonal antibody, VEGF Ab) and/or an angiopoietin antagonist (Ang-2) were administered to rhesus monkeys: (1) locally via injection into the preovulatory follicle at midcycle or the developing corpus luteum at the midluteal phase; or (2) systemically via subcutaneous injection in the early follicular phase or at midcycle during the natural menstrual cycle. Compared to controls, intrafollicular injection of TNP-470 or sVEGFR-1 decreased circulating progesterone (P) levels in the subsequent luteal phase. Treatment with sVEGFR-1, but not TNP-470, also decreased the incidence of ovulation. Intrafollicular injection of Ang-2 also prevented ovulation, as well as any functional luteal phase. In the absence of elevated P, serum estradiol levels rose to peak levels 11-12 days post-Ang-2 treatment, at which time another large antral follicle was observed on the contralateral (noninjected) ovary. Intraluteal and systemic injection of VEGF antagonists alone or with Ang-2 had minimal effects. Thus, anti-angiogenic factors can act locally in the primate follicle to disrupt the gametogenic (oocyte release) and endocrine (steroid) functions of the ovary. However, further studies are needed to optimize delivery of angiogenic agents before they can be meaningfully evaluated as possible contraceptive agents.

    AB - To determine if anti-angiogenic agents disrupt primate ovarian function, vehicle or a general angiostatic compound (TNP-470), specific antagonists of vascular endothelial growth factor (soluble VEGF receptor-1, sVEGFR-1; anti-VEGF monoclonal antibody, VEGF Ab) and/or an angiopoietin antagonist (Ang-2) were administered to rhesus monkeys: (1) locally via injection into the preovulatory follicle at midcycle or the developing corpus luteum at the midluteal phase; or (2) systemically via subcutaneous injection in the early follicular phase or at midcycle during the natural menstrual cycle. Compared to controls, intrafollicular injection of TNP-470 or sVEGFR-1 decreased circulating progesterone (P) levels in the subsequent luteal phase. Treatment with sVEGFR-1, but not TNP-470, also decreased the incidence of ovulation. Intrafollicular injection of Ang-2 also prevented ovulation, as well as any functional luteal phase. In the absence of elevated P, serum estradiol levels rose to peak levels 11-12 days post-Ang-2 treatment, at which time another large antral follicle was observed on the contralateral (noninjected) ovary. Intraluteal and systemic injection of VEGF antagonists alone or with Ang-2 had minimal effects. Thus, anti-angiogenic factors can act locally in the primate follicle to disrupt the gametogenic (oocyte release) and endocrine (steroid) functions of the ovary. However, further studies are needed to optimize delivery of angiogenic agents before they can be meaningfully evaluated as possible contraceptive agents.

    KW - Angiopoietin-2

    KW - Corpus luteum function

    KW - Ovarian disruption

    KW - Ovulation

    KW - Rhesus monkeys

    KW - Vascular endothelial growth factor

    KW - VEGF

    UR - http://www.scopus.com/inward/record.url?scp=15744387584&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=15744387584&partnerID=8YFLogxK

    U2 - 10.1016/j.contraception.2004.12.017

    DO - 10.1016/j.contraception.2004.12.017

    M3 - Article

    VL - 71

    SP - 239

    EP - 248

    JO - Contraception

    JF - Contraception

    SN - 0010-7824

    IS - 4

    ER -